Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
281 SEK | +0.07% | +7.66% | +5.24% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The firm trades with high earnings multiples: 28.09 times its 2024 earnings per share.
- With an enterprise value anticipated at 4.42 times the sales for the current fiscal year, the company turns out to be overvalued.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+5.24% | 8.71B | B+ | ||
-4.66% | 86.13B | A- | ||
+1.32% | 39.82B | A- | ||
-19.27% | 30.42B | B- | ||
+57.86% | 25.23B | A | ||
-16.09% | 15.36B | C | ||
-9.14% | 11.95B | D+ | ||
-17.69% | 11.6B | B- | ||
-43.00% | 11.51B | B | ||
-8.42% | 8.12B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SOBI Stock
- Ratings Swedish Orphan Biovitrum AB